Incyte Corporation

Incyte Corporation is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Incyte Corp. is an American multinational pharmaceutical company. The company operates manufacturing, research, and development into biopharmaceutical medical solutions in areas like autoimmunity, inflammation, and oncology.

Ticker: INCY

Humankind Value: $36.5 B

Revenue: 2.4 B

Market Cap: $16.6 B

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Incyte Corp. has earned a spot in our top 100. Notable sources of positive value are Healthcare R&D ($28.0 B), Pharmaceuticals ($7.9 B), and Economic Value ($552.4 M). Healthcare is a central component of our measure of Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. Incyte produces economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. Positive value from Healthcare R&D and Pharmaceuticals includes the impact of an estimated 744,999.8 additional years lived by people worldwide. Downsides for this company are associated with Greenhouse Gases (-$184.6 M) and Air Pollution (-$37.8 M). Healthcare R&D, Pharmaceuticals, Economic Value, Greenhouse Gases, and Air Pollution are attached to this company as a result of its direct business activities.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

How Methodology Drives the Rankings